GENOMICA S.A.U. aus Madrid auf der MEDICA 2018 in Düsseldorf -- MEDICA - Weltforum der Medizin

GENOMICA S.A.U.

Parque Empresarial Alvento, Edificio B, Vía de los Poblados 1, 1ª Planta, 28033 Madrid
Spanien
Telefon +34 91 6748990
Fax +34 91 6748991
info.genomica@genomica.com

Dieser Aussteller ist Mitaussteller von
SCIENION AG

Hallenplan

MEDICA 2018 Hallenplan (Halle 3): Stand A42

Geländeplan

MEDICA 2018 Geländeplan: Halle 3

Unser Angebot

Produktkategorien

  • 03  Diagnostika
  • 03.06  Gentests, molekularbiologische Diagnostik
  • 03.06.03  Polymerase chain reaction (PCR)

Polymerase chain reaction (PCR)

Unsere Produkte

Produktkategorie: Polymerase chain reaction (PCR)

CLART (Clinical Array Technology)

CLART® is a low density microarray-based platform for clinical
use that allows the detection of multiple targets in a single
test. Sample processing is straightforward and the analysis
and interpretation of results are performed automatically by a
reader (CAR® or CLINICAL ARRAY READER) running tailor-made
software. Its simplicity makes this technology suitable for every
molecular diagnostics laboratory.

CLART® provides fast, sensitive and accurate results that meet
the highest quality standards, and allows the clinician to take the
right decisions on time.

CLART is divided in Microbiology kits for diverse pathogenes detection and an Oncology line named CLART CMA to detect mutations in oncogenes.  

Mehr Weniger

Über uns

Firmenporträt

GENOMICA is the first Spanish company in Molecular Diagnostics that develops and manufactures CLART, its own line of IVD kits. The company is currently commercializing them in more than 40 countries worldwide and dispose of subsidiaries offices in China, Brazil, and Sweden. The company is a reference globally as a reliable and competitive kits supplier. Its kits are used in screening programs under its own brand. Also, it has OEM agreements with international brands. 

GENOMICA is committed to the highest quality standards and put a huge effort into research and development. The company is now working in a breakthroug development: NEDxA, its very first POCT device.

Mehr Weniger